Biotech Archives - Page 657 of 733

1 minute read

Aytu BioPharma Announces Addition Of Fourth Patent License For AR101/Enzastaurin

September 14, 8:09 AM

ENGLEWOOD, CO / ACCESSWIRE / September 14, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, with a

AYTU

1 minute read

After Investor Flak, German Healthcare Giant Bayer Starts Hunt For New CEO: Report

By Vandana Singh

September 14, 7:58 AM

Bayer AG (OTC:BAYRY) has started a hunt for CEO Werner Baumann’s successor, Bloomberg News reported, citing people close to the…

BAYRY

1 minute read

BioCardia Announces CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data To Be Presented At Heart Failure Society Of America Annual Meeting

By Bill Haddad

September 14, 7:02 AM

Sunnyvale, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today

BCDA

1 minute read

NGM Bio Presents Preliminary Data From NGM120 Combo Trial In Pancreatic Cancer

By Vandana Singh

September 14, 6:44 AM

NGM Biopharmaceuticals Inc (NASDAQ:NGM) announced updated preliminary findings from its Phase 1b dose escalation trial of NGM120 in metastatic pancreatic cancer.…

NGM

3 minute read

Important Biotech Catalysts For September 13, 2022 – End Of The Day Summary

By Ragothaman Srinivasan

September 13, 6:45 PM

Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety…

AKRO

2 minute read

GENFIT Gets FDA Orphan Drug Status For Liver Disease Candidate

By Ragothaman Srinivasan

September 13, 5:18 PM

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to GENFIT’s (NASDAQ: GNFT) drug candidate GNS5611 (ezurpimtrostat) for the treatment of cholangiocarcinoma.

GNFT

1 minute read

Conformis Shares Shoot Higher Following FDA Clearance For Actera Hip System

By Ragothaman Srinivasan

September 13, 4:58 PM

Conformis (NASDAQ: CFMS) has received 510(k) clearance from the U.S. Food and Drug Administration for its Actera Hip System. Actera utilizes an advanced tri-taper femur stem design that facilitates direct anterior approach total hip arthroplasties, and provides an additional stem option to orthopedic surgeons.

CFMS

2 minute read

Conformis Actera Hip System Receives 510(k) Clearance From The U.S. FDA

By Benzinga Newsdesk

September 13, 4:30 PM

Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, today announced that it has received 510(k) clearance from the U.S. Food and Drug

CFMS

2 minute read

Syros Shares Soar As FDA Grants Orphan Drug Status To Pancreatic Cancer Candidate

By Ragothaman Srinivasan

September 13, 4:23 PM

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Syros Pharmaceuticals (NASDAQ: SYRS) lead candidate SY-5609 for the treatment of pancreatic cancer.

SYRS

2 minute read

Syros Receives FDA Orphan Drug Designation For SY-5609 For The Treatment Of Pancreatic Cancer

By Benzinga Newsdesk

September 13, 4:01 PM

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug

SYRS